TITLE:
Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad
AUTHORS:
Chatté Adawaye, Kamangu Erick, Soudy I. Djibrine, Aoudalkarim Moussa Chahad, Ali Mahamat Moussa, Tchombou HZ Bertin, Vaira Dolores, Moutschen Michel
KEYWORDS:
Plasma, Viral Load, Triomune, Antiretroviral Therapy, Virological Failure, ARVs, HIV-1, First Line
JOURNAL NAME:
World Journal of AIDS,
Vol.4 No.3,
August
18,
2014
ABSTRACT: Contexte:The fight against
HIV/AIDS epidemics is one of the greatest challenges of this century. The
epidemic affects generally under-developed countries, and Sub-Saharan Africa
are the most concerned. The combined marketed form known as Triomune was used
as first-line treatment in several sub-Saharan African Countries (60% of VIH
infected people), including Chad. However, no evaluation has been done for that
treatment in the country. Objective: To evaluate the efficacy and safety
immuno-virological of Triomune at the General Hospital in N’Djamena/Chad.
Methods: 48 HIV-1 positive patients eligible for ARV treatment were enrolled in
our study, and they have been then followed for 8 months. We have measured in
these patients the CD4 cell count before treatment and at the 8th month of
treatment. After 8 months of treatment, we have also evaluated the Lymphocyte T
CD4 and the plasma viral load (VL). Comparisons of means of CD4 lymphocytes and
plasma CV (≥1000 copies/ml) were used to define treatment failure.Results:48
patients were under Triomune regime. The average CD4 count was decreased from
462 ± 179.22 [56 - 981] cells/mm3before treatment to 327.23 ±
153.77 [10 - 1008] cells/mm3at the 8th month of treatment. The
mean plasma viral load for patients was 66008.62 copies/ml. The failure rate to
Triomune was 43.75% (21/48).Conclusion:Aside from the side effects
already described for Triomune, our study reveals a high treatment failure
rate. Hence, there is the need of regular revisions of therapeutic regime
administer in the first intention.